title: Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.
abstract: BACKGROUND
  Interleukin (IL)-5 is believed to be a key cytokine in eosinophil inflammatory infiltration in asthma. Previous clinical trials have evaluated the efficacy and safety of mepolizumab, a monoclonal antibody against IL-5, in patients with asthma. However, most of these studies were small, the conclusions were inconsistent, and the precise effects are therefore debatable.
  
  
  METHODS
  A meta-analysis of randomized placebo-controlled trials was conducted to evaluate the effect of intravenous infusion of mepolizumab on clinical outcomes in patients with asthma. Trials were searched in PubMed, Embase, Web of Science, Cochrane CENTRAL, Scopus, reviews, and reference lists of relevant articles. The outcome variables analyzed included eosinophil counts in blood and sputum, airways outcome measures, exacerbations, asthma control, and quality of life scores.
  
  
  RESULTS
  Seven studies met final inclusion criteria (total n = 1131). From the pooled analyses, mepolizumab significantly reduced eosinophils in blood (MD -0.29×10(9)/L, 95% CI -0.44 to -0.14×10(9)/L, P = 0.0001) and sputum (MD -6.05%, 95% CI -9.34 to -2.77%, P = 0.0003). Mepolizumab was also associated with significantly decreased exacerbation risk than placebo (OR 0.30, 95%CI 0.13 to 0.67, P = 0.004), and with a significant improvement in the scores on the Asthma Quality of Life Questionnaire (AQLQ) (MD 0.26, 95% CI 0.03 to 0.49, P = 0.03) in patients with eosinophilic asthma. There were no statistical differences between the groups with respect to FEV1, PEF, or histamine PC20 (all P>0.05), and a non-significant trend for improvement in scores on the Juniper Asthma Control Questionnaire (JACQ) (MD -0.21, 95% CI -0.43 to 0.01, P = 0.06) in the mepolizumab group was observed.
  
  
  CONCLUSIONS
  Mepolizumab reduces the risk of exacerbations and improves quality of life in patients with eosinophilic asthma, but no significant improvement in lung function outcomes was observed. Further research is required to establish the possible role of anti-IL-5 as a therapy for asthma.
authors.affiliation: Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: Yao
authors.initials: Y
authors.lastname: Liu
authors.forename: Song
authors.initials: S
authors.lastname: Zhang
authors.forename: Dao-wei
authors.initials: DW
authors.lastname: Li
authors.forename: Shu-juan
authors.initials: SJ
authors.lastname: Jiang
mesh_terms: D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D001772:Blood Cell Count; D018450:Disease Progression; D004804:Eosinophils / Q000187:drug effects; D005541:Forced Expiratory Volume / Q000187:drug effects; D006632:Histamine / Q000378:metabolism; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D010919:Placebos; D017594:Publication Bias; D016032:Randomized Controlled Trials as Topic; D013183:Sputum / Q000166:cytology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; D010919:Placebos; D006632:Histamine; C434107:mepolizumab
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: J Clin Invest. 1991 May;87(5):1541-6
references.pmid: 2022726
references.citation: Am J Respir Crit Care Med. 2003 Jan 15;167(2):199-204
references.pmid: 12406833
references.citation: Lancet. 2012 Aug 18;380(9842):651-9
references.pmid: 22901886
references.citation: J Allergy Clin Immunol. 2010 Apr;125(4):803-13
references.pmid: 20371394
references.citation: Eur Respir J. 2003 May;21(5):799-803
references.pmid: 12765424
references.citation: Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):704-8
references.pmid: 9309982
references.citation: N Engl J Med. 1990 Oct 11;323(15):1033-9
references.pmid: 2215562
references.citation: Lancet. 1982 Jul 3;2(8288):11-6
references.pmid: 6177986
references.citation: Blood. 1992 Jun 1;79(11):2952-9
references.pmid: 1316789
references.citation: Lancet. 2002 Nov 30;360(9347):1715-21
references.pmid: 12480423
references.citation: Respir Med. 2005 May;99(5):553-8
references.pmid: 15823451
references.citation: Am J Respir Crit Care Med. 2007 Dec 1;176(11):1062-71
references.pmid: 17872493
references.citation: N Engl J Med. 2009 Mar 5;360(10):985-93
references.pmid: 19264687
references.citation: Clin Sci (Lond). 2002 Aug;103(2):201-11
references.pmid: 12149112
references.citation: Eur Respir J. 2006 Mar;27(3):483-94
references.pmid: 16507847
references.citation: Am Rev Respir Dis. 1993 Aug;148(2):401-6
references.pmid: 8342904
references.citation: Lancet. 2000 Dec 23-30;356(9248):2144-8
references.pmid: 11191542
references.citation: Lancet. 1999 Nov 27;354(9193):1896-900
references.pmid: 10584742
references.citation: Am J Respir Crit Care Med. 2000 Jan;161(1):64-72
references.pmid: 10619799
references.citation: Blood. 1989 May 1;73(6):1504-12
references.pmid: 2653458
references.citation: J Allergy Clin Immunol. 2005 Apr;115(4):720-7
references.pmid: 15805990
references.citation: Am Rev Respir Dis. 1993 Apr;147(4):832-8
references.pmid: 8466117
references.citation: Thorax. 2006 Nov;61(11):992-9
references.pmid: 17071835
references.citation: J Exp Med. 1988 May 1;167(5):1737-42
references.pmid: 2835420
references.citation: N Engl J Med. 2009 Mar 5;360(10):973-84
references.pmid: 19264686
references.citation: Am Rev Respir Dis. 1993 Apr;147(4):896-900
references.pmid: 8385431